Oncology Central

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?


In non-small-cell lung cancer (NSCLC), the discovery that EGF receptor (EGFR) signaling plays a key role in regulating cell proliferation, differentiation and tumorigenesis has emphasized the importance of targeted therapy. Small molecule tyrosine kinase inhibitors of EGFR (EGFR–TKIs), such as gefitinib and erlotinib, compete with ATP for binding to the tyrosine kinase pocket of the receptor, thereby inhibiting receptor kinase activity and EGFR signaling.

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.